Evaluation Of Nanoparticles, Liposomes, Or Transdermal Patches For Improved Bioavailability.

Original Article

Abstract

Background: pharmacology achieving the desired therapeutic effect of a drug is hindered by the difficulties associated with poor bioavailability, particularly with low-solubility and low-stability drugs. Innovative delivery mechanisms, including nanoparticles, liposomes, and transdermal patches, are designed to enhance stability and solubility, and achieve controlled release controlled release of medications. This research investigates the effectiveness of these formulations. 

Objectives: To determine the effectiveness of nanoparticles, liposomes, and transdermal patches on the bioavailability of therapeutic drugs. 

Methodology: This Randomized controlled trial Conducted in the Department of Biochemistry Bacha Khan Medical College Mardan from jan 2023 to june 2023. Blood samples were obtained from 100 adult participants, who were randomly assigned to three groups: transdermal patches (n = 33), liposomes (n = 34), and nanoparticles (n = 33). These samples were collected at baseline, and 2, 6, and 12 hours after drug administration. Subsequently, the samples were analyzed to determine drug concentrations via high-performance liquid chromatography (HPLC). Bioavailability estimation was calculated from peak plasma concentration (Cmax) and area under the curve (AUC). ANOVA was used for statistical analysis, with a significance level of p < 0.05.

Results: The participants mean age was 45.7 years with a standard deviation of 12.5 years. The nanoparticle group had a significantly greater bioavailability than the liposomes and transdermal patches (p < 0.05). The mean Cmax for the nanoparticle group was 250 ± 40 mg/mL, for the liposome group 180 ± 35 mg/mL, and for the transdermal patch 150 ± 30 mg/mL. The mean AUC for the nanoparticle group was 1500 ± 220, for the liposome group 1200 ± 200, and for the transdermal patch 1000 ± 180 ng•h/mL. The time to peak concentration (Tmax) was 2 hours for the nanoparticle group, which was the lowest of all groups. There were no statistically significant differences between the groups with respect to the adverse effects, indicating that all formulations were well tolerated.

Conclusion: Innovations in transdermal patches and liposomes provide more opportunities to enhance drug bioavailability; yet, the delivery system incorporating nanoparticles remains superior to these methods. Improvement of systemic drug exposure can be achieved with the use of nanoparticles, signaling the potential for a significant shift in delivery methods for pharmaceuticals. However, ongoing adaptations, as well as prolonged studies, are still required for all delivery methods studied.